Comparison of serum iron, hemoglobin, ferritin and CRP levels in prostate cancer patients with a control group

Abstract

Aim: The aim of the study was to investigate the differences between serum iron, ferritin, hemoglobin, and CRP levels between patients with new prostate cancer diagnosis and a control group.

Materials and Methods: This study was cross-sectional and prospectively recorded data from 323 patients with new prostate cancer (PCa) diagnosis and 346 healthy controls between April 2015 and June 2022. Parameters like age, PSA value, serum iron, ferritin and hemoglobin were compared between groups.

Results: The age distribution in groups was identified as 67.19±8.33 years in the PCa group and 62.11±8.16 years in the control group (p<0.001). The distribution of PSA (mean±SD) according to groups was determined as 8.40±41.80 (3.54-680) and 0.90±1.02 (0.13-2.94) ng/ml, respectively (p<0.001). The distribution of Fe levels in the groups was identified as 81.36±37.80 (21-283) and 90.96±31.23 (33-162) mcg/dL (p= 0.014). Hgb values were 14.06±1.56 (8.50-16.70) and 14.58±1.30 (8.98-17.20) g/dl (p<0.001). Ferritin values (median±IQR) were identified as 60.30±72.57 (3.6-546) and 54.60±64.04 (6.16-572) ml/ng, respectively (p=0.427).

Conclusion: It was identified that the iron and Hgb levels in serum of patients with new prostate cancer diagnosis were reduced compared to the control group. Low serum iron was identified to possibly be a risk factor for prostate cancer.